Universe Pharmaceuticals INC (NASDAQ:UPC) Short Interest Update

Universe Pharmaceuticals INC (NASDAQ:UPC) saw a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 35,401 shares, a growth of 454.7% from the July 30th total of 6,382 shares. Currently, 1.7% of the shares of the company are short sold. Based on an average daily trading volume, of 2,816,444 shares, the days-to-cover ratio is presently 0.0 days.

Universe Pharmaceuticals Stock Down 5.3%

Universe Pharmaceuticals stock traded down $0.28 during midday trading on Thursday, hitting $5.04. The stock had a trading volume of 51,743 shares, compared to its average volume of 2,087,552. Universe Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $17.96. The firm’s fifty day moving average is $5.04 and its two-hundred day moving average is $3.67. The company has a current ratio of 4.05, a quick ratio of 3.90 and a debt-to-equity ratio of 0.04.

Universe Pharmaceuticals (NASDAQ:UPC) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($1.38) earnings per share for the quarter. The business had revenue of $4.52 million for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.